Hundreds of people a year check into a single hospital in Yunnan province. They arrive complaining of visions. Not just any visions. They see tiny human figures. These little people march across tables, dance on furniture, climb curtains. The patients ate a local delicacy. A prized bolete mushroom known in markets as jian shou qing. It bruises blue when handled. Locals prize its flavor. Yet it triggers hallucinations that match no familiar toxin profile.
The mushroom is Lanmaoa asiatica. It belongs to a genus of boletes more closely related to the common porcini than to any psilocybin-containing species. Genome sequencing confirms it. No biosynthetic genes for psilocybin. None for ibotenic acid either. Still the reports persist. Consistent. Detailed. Documented across hospitals and historical texts.
One discovery reorders assumptions about how fungi alter human perception
Researchers from the University of Utah sequenced 53 specimens from the Lanmaoa genus. They built a phylogeny using 1,515 single-copy orthologous genes. The work expanded the recognized species count to 17. Six names got updated. Four species proved new to science. Two of them, Lanmaoa fallax and Lanmaoa carbonilivor, received formal descriptions. The paper appeared in Mycologia.
Yet the sequencing delivered a puzzle. Lanmaoa asiatica carries none of the genetic machinery known to produce established hallucinogens. Regional accounts tell a different story. More than a hundred cases treated annually at one Yunnan facility. In hospital records, 96 percent of those who ate the mushroom and sought help reported seeing little people. The clinical label is Lilliputian hallucination. It draws from the six-inch inhabitants in Gulliver’s Travels. The visions sharpen when patients close their eyes.
But these aren’t isolated anecdotes. Similar reports surface from the Philippines. An ancient Chinese text describes comparable effects. The mushroom grows across Asia. Specimens have turned up in the Americas and Europe. Its distribution spans continents. So does the genus. That breadth makes the unknown chemistry all the more striking.
Psychedelics.co.uk first highlighted the case in detail on June 5, 2026. The outlet noted that “Hundreds of people a year are hospitalised seeing little people after a meal of a prized Yunnan bolete.” It quoted the sharpening effect with eyes closed. And it emphasized the core contradiction. “Lanmaoa asiatica carries none of the known psilocybin or ibotenic acid biosynthetic genes, yet regional reports consistently describe hallucinogenic effects pointing to an unknown pathway.”
The article framed Lanmaoa as potentially a third independent line of psychoactive fungi. Separate from the psilocybin producers in genera such as Psilocybe, Panaeolus, Gymnopilus and Inocybe. Separate also from the ibotenic acid and muscimol pathway in Amanita. A globally distributed genus of boletes, it suggested, “may represent a third family of psychoactive mushrooms, working through a chemistry that no one understands yet.”
That claim lands at a moment when interest in fungal compounds runs high. Recent studies probe compounds beyond psilocybin itself. Oregon State University researchers examined “magic mushroom” edibles sold in smoke shops. They found no psilocybin. No muscimol either. Instead the products contained caffeine, hemp extracts and kava. The analysis, reported September 11, 2025 by Oregon State University Newsroom, underscores how little regulators and consumers know about what actually reaches the market.
Other work explores entourage effects. Scientists debate whether minor tryptamines such as baeocystin, norbaeocystin or aeruginascin shape the overall experience in psilocybin mushrooms. A 2025 piece in Chemical & Engineering News asked directly, “Is there more to magic mushrooms than psilocybin?” It cited skepticism from experts at the Usona Institute and Helmholtz Centre. Concentrations of those analogs often fall far below psilocybin levels. Some metabolites may not even cross the blood-brain barrier effectively. Yet the discussion continues. The Lanmaoa case adds pressure. Here stands a mushroom that produces vivid, specific hallucinations with zero trace of the usual suspects.
And the effects differ. Psilocybin trips typically involve geometric patterns, time distortion, ego dissolution. Lilliputian hallucinations center on tiny animated figures performing mundane or whimsical actions. Patients remain oriented enough to seek medical help. The phenomenon appears self-limiting. No widespread reports of lasting harm beyond the initial distress. Still, hundreds of hospitalizations yearly signal a public-health wrinkle in a region where the bolete holds culinary esteem.
Taxonomists had long struggled with Lanmaoa. The genus resisted clean phylogenetic placement. The Utah team’s use of 21 type specimens helped resolve relationships. They renamed species. Clarified boundaries. The work reveals a lineage that evolved its psychoactive capacity independently. Closer to edible porcini than to any known hallucinogenic mushroom. That phylogenetic distance supports the idea of a novel biosynthetic route.
So what compound actually drives the visions? Blood and tissue profiling from affected patients has been limited. Fruiting-body chemistry studies have turned up nothing conclusive. The genome offers no obvious candidates. Researchers face a blank slate. One that could rewrite assumptions about fungal secondary metabolism.
Parallel research on other genera adds context. Aeruginascin, first identified in Inocybe aeruginascens, has drawn attention for producing more consistently euphoric experiences than pure psilocybin. Reviews in psychiatric journals explore its potential entourage role. Yet aeruginascin is a tryptamine derivative. Lanmaoa lacks even that class of machinery.
Recent psilocybin studies continue to dominate headlines. One case report described an 80-year-old Alzheimer’s patient who regained lost functions temporarily after a high dose of psilocybin-containing mushrooms. The Frontiers in Neuroscience paper appeared in 2026. Another study found psilocybin dissolved in water made mangrove rivulus fish less aggressive and more sedentary. These findings illustrate the broad biological reach of known compounds. They also highlight how much remains unexplored outside established pathways.
Market data reflect surging interest. A RAND Corporation report released January 2026 found psilocybin the most-used psychedelic among U.S. adults in 2025. Amanita muscaria ranked in the top five despite its distinct chemistry. Consumers chase effects. Regulators scramble to understand products. Against that backdrop, a bolete that confounds every known mechanism demands attention.
Hospital records from Yunnan provide the clearest signal. The 96 percent figure stands out. So does the specific phenomenology. Tiny people. Marching. Dancing. The consistency across unrelated individuals points to a reproducible pharmacological action. Not mass hysteria. Not misidentification with a psilocybin species. The blue bruising and market name tie directly to Lanmaoa asiatica.
Taxonomic clarity now exists. The genus sits firmly among boletes. Its psychoactive member evolved its trait on a separate branch. That fact alone widens the picture of natural product chemistry. Fungi have invented ways to affect human brains at least three times. Each route distinct. Each worthy of study.
Practical questions follow. Should foragers in Asia receive warnings? Can the active principle be isolated without the mushroom’s variable potency? Might it offer therapeutic clues different from psilocybin? Current data cannot answer. The genome sequence marks only a starting line.
Scientists at Utah and their collaborators performed careful work. They sequenced broadly. They incorporated historical specimens. Their phylogeny holds. Yet the chemical mystery deepens with every confirmed case. Hundreds hospitalized. Visions of miniature worlds. A prized edible that turns unsettling.
The Lanmaoa story exposes gaps. In mycological knowledge. In toxicological screening. In regulatory oversight of wild mushrooms. It also hints at untapped diversity. If one bolete hides a novel hallucinogen, how many others do the same? The porcini on your plate suddenly feels less ordinary.
Further sequencing of related species could reveal when the trait arose. Comparative metabolomics on fresh specimens might finally identify the molecule. Clinical follow-up with affected patients could map the hallucination profile against known receptor pathways. Each step carries risk of disappointment. Each also carries potential to expand the map of mind-altering natural products.
For now the visions remain unexplained. Tiny figures continue to appear in hospital rooms across Yunnan. Patients recover. The mushroom keeps its secret. And researchers hold a genome that says, in effect, we have no idea how this works. That admission may prove the most valuable result of all.
WebProNews is an iEntry Publication